High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the multicenter eastern cooperative oncology group phase II trial E2696 Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Cancer Vaccines
  • G(M2) Ganglioside
  • Interferon-alpha
  • Melanoma
  • Skin Neoplasms

abstract

  • Cox analysis of the results of the combination with IFNalpha2b show improvement in the relapse-free survival of patients with very high-risk melanoma (including those with resectable M1 disease).

publication date

  • March 2001

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 11230488

Additional Document Info

start page

  • 1430

end page

  • 6

volume

  • 19

number

  • 5